Coronavirus Disease 2019 (COVID-19) in a Renal Transplant Patient

Avantika Chenna; Venu Madhav Konala; Vijay Gayam; Srikanth Naramala; Sreedhar Adapa

doi:10.7759/cureus.8038

Coronavirus Disease 2019 (COVID-19) in a Renal Transplant Patient

Cureus. 2020 May 9;12(5):e8038. doi: 10.7759/cureus.8038.

Authors

Avantika Chenna^{1

2}, Venu Madhav Konala^{3

4}, Vijay Gayam⁵, Srikanth Naramala⁶, Sreedhar Adapa⁷

Affiliations

¹ Nephrology, Phoebe Putney Memorial Hospital, Albany, USA.
² Nephrology, Medical College of Georgia, Augusta, USA.
³ Hematology and Oncology, Ashland Bellefonte Cancer Center, Ashland, USA.
⁴ Hematology and Oncology, King's Daughters Medical Center, Ashland, USA.
⁵ Internal Medicine, Interfaith Medical Center, New York, USA.
⁶ Rheumatology, Adventist Medical Center, Hanford, USA.
⁷ Nephrology, Kaweah Delta Medical Center, Visalia, USA.

Abstract

Coronavirus disease 2019 (COVID-19) has resulted in significant morbidity and mortality worldwide. Transplant patients are particularly at a higher risk of contracting COVID-19 because of their immunosuppressed state, and they have the propensity to develop opportunistic infections. The pre-immunosuppressed state, along with other existing comorbidities, can influence the outcomes of COVID-19 in transplant patients. We describe a case of a renal transplant patient who developed COVID-19. Real-time nucleic acid testing (NAT) should be done in deceased and living donors. The most common management strategy is the modification of immunosuppression along with current experimental strategies for COVID-19.

Keywords: acute respiratory distress syndrome; coronavirus; covid-19; renal transplant.

Publication types

Case Reports